Arcturus' topical dexchlorpheniramine enters Phase Ib/II trials as anti-itch treatment.
This article was originally published in The Tan Sheet
Executive Summary
ARCTURUS BEGINS TOPICAL DEXCHLORPHENIRAMINE PHASE Ib/II STUDY as an anti-itch treatment for contact and atopic dermatitis, the dermatological R&D company announced Jan. 31. Arcturus Pharmaceutical said it expects the trial, which is a dose-escalating study in patients with atopic dermatitis, to be completed by the second half of 1995. The company hopes to begin Phase III efficacy trials by the end of the year.